Financière de Tubize S.A.
TUB
Κατάταξη σε μετοχές
#2119
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Τιμή μετοχής
$217.90
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$9.70B
Αλλαγή (1 ημέρα)
5.57%
Αλλαγή (1 έτος)
-19.89%
Χώρα
BE
Εμπόριο Financière de Tubize S.A. (TUB)
Κατηγορία
Healthcare
EPS για Financière de Tubize S.A. (TUB)
EPS στις June 2026 TTM: $2.62
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Financière de Tubize S.A., το τρέχον EPS της εταιρείας (TTM) είναι $2.62. Στο τέλος του 2023, η εταιρεία είχε EPS $2.19, αύξηση σε σχέση με το EPS του 2022 που ήταν $2.05.
Ιστορικό EPS της Financière de Tubize S.A. από 2003 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $2.62 | 24.83% |
| 2024 | $2.10 | -3.97% |
| 2023 | $2.19 | 6.83% |
| 2022 | $2.05 | -4.16% |
| 2021 | $2.14 | -69.99% |
| 2020 | $7.12 | -25,913.77% |
| 2019 | $-0.03 | -100.37% |
| 2018 | $7.37 | -4.38% |
| 2017 | $7.70 | 79.89% |
| 2016 | $4.28 | -17.32% |
| 2015 | $5.18 | 214.76% |
| 2014 | $1.65 | -13.29% |
| 2013 | $1.90 | -17.32% |
| 2012 | $2.30 | 22.27% |
| 2011 | $1.88 | 198.71% |
| 2010 | $0.63 | -88.03% |
| 2009 | $5.25 | -18,644.17% |
| 2008 | $-0.03 | -102.18% |
| 2007 | $1.30 | -90.76% |
| 2006 | $14.08 | 80.81% |
| 2005 | $7.79 | 111.12% |
| 2004 | $3.69 | -20.63% |
| 2003 | $4.65 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $17.32 | 560.72% |
US
|
|
| $-7.98 | -404.42% |
US
|
|
| $-5.29 | -301.80% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 958.21% |
NL
|
